We examined the function of ␣ 4 ␤ 1 integrin in angiogenesis and in mediating endothelial cell responses to the angiogenesis modulators, thrombospondin-1 and thrombospondin-2. ␣ 4 ␤ 1 supports adhesion of venous endothelial cells but not of microvascular endothelial cells on immobilized thrombospondin-1, vascular cell adhesion molecule-1, or recombinant N-terminal regions of thrombospondin-1 and thrombospondin-2. Chemotactic activities of this region of thrombospondin-1 and thrombospondin-2 are also mediated by ␣ 4 ␤ 1 , whereas antagonism of fibroblast growth factor-2-stimulated chemotaxis is not mediated by this region. Immobilized N-terminal regions of thrombospondin-1 and thrombospondin-2 promote endothelial cell survival and proliferation in an ␣ 4 ␤ 1 -dependent manner. Soluble ␣ 4 ␤ 1 antagonists inhibit angiogenesis in the chick chorioallantoic membrane and neovascularization of mouse muscle explants. The latter inhibition is thrombospondin-1-dependent and not observed in explants from thrombospondin-1 Ϫ/Ϫ mice. Antagonizing ␣ 4 ␤ 1 may in part block proangiogenic activities of thrombospondin-1 and thrombospondin-2, because N-terminal regions of thrombospondin-1 and thrombospondin-2 containing the ␣ 4 ␤ 1 binding sequence stimulate angiogenesis in vivo. Therefore, ␣ 4 ␤ 1 is an important endothelial cell receptor for mediating motility and proliferative responses to thrombospondins and for modulation of angiogenesis. (Circ Res. 2004;94:462-470.) 
A ngiogenesis, the outgrowth of new blood vessels from existing vasculature, is an important event in normal development and pathological conditions such as cancer. Angiogenesis is regulated by interactions of endothelial cells with growth factors and components of the extracellular matrix that either promote or inhibit angiogenesis. 1 Thrombospondins (TSPs) have diverse effects on cell behavior. 2 Two members of this family, TSP1 and TSP2, are known to modulate angiogenic responses. TSP1 and TSP2 have antiangiogenic as well as antitumor activities in several xenograft models. [3] [4] [5] [6] TSP1 and TSP2 presumably regulate angiogenesis through their modulation of endothelial cell proliferation, [7] [8] [9] motility, 7,10 and apoptosis. 11, 12 Based on in vitro and in vivo angiogenesis assays, antiangiogenic activities of TSP1 and TSP2 have been mapped to the procollagen-homology domain and the type 1 repeats. [13] [14] [15] Inhibition is mediated through interactions with CD36 and proteoglycan receptors. 14 -16 However, the N-terminal domain of TSP1 stimulates angiogenesis, 17, 18 in part through its interaction with ␣ 3 ␤ 1 integrin. 18 TSP1 may also influence their behavior through additional TSP receptors expressed on endothelial cells, including LDL receptor-related protein, ␣ v ␤ 3 and ␣ 6 ␤ 1 integrins, and CD47 or by activating latent TGF␤. 2, 19 The role of TSP1 in angiogenesis is therefore complex, and includes both proangiogenic and antiangiogenic activities. Acquisition of an angiogenic phenotype is frequently associated with decreased expression of TSP1 or TSP2, 20 -22 whereas restoration of TSP1 levels in tumor cells reduces angiogenesis and tumor progression. 3 Correlating levels of TSP1 with tumor progression and clinical prognosis in cancer patients, however, has yielded conflicting results. [23] [24] [25] [26] To understand its role in cancer and to define a molecular basis for the complex endothelial cell responses to TSP1, we must understand how the simultaneous signals from multiple TSP1 receptors are integrated. The complete identification of endothelial cell TSP1 receptors is the critical first step toward this goal.
In addition to the known endothelial cell receptors, TSP1 interacts with ␣ 4 ␤ 1 integrin on T cells 27 and some cancer cells. 28, 29 A sequence in TSP1 recognized by ␣ 4 ␤ 1 was mapped to the N-terminal domain and is also conserved in TSP2. 27 Leukocyte ␣ 4 ␤ 1 is a well-characterized counter receptor for endothelial cell vascular cell adhesion molecule-1 (VCAM-1), 30 but its function in endothelial cells is poorly understood. The ␣ 4 integrin subunit is expressed in endothelial cells in vitro 31, 32 and in vivo, 33 suggesting that ␣ 4 ␤ 1 could be an additional receptor for TSPs in these cells. We therefore examined the role of ␣ 4 ␤ 1 in venous and microvascular endothelial cell responses to TSP1 and TSP2 in vitro. Our data show that ␣ 4 ␤ 1 is an endothelial TSP receptor that regulates cell proliferation, adhesion, and migration. In vivo and ex vivo angiogenesis assays indicate that ␣ 4 ␤ 1 plays important roles in angiogenesis and its regulation by TSP1. Figure 1 . ␣ 4 ␤ 1 integrin mediates large-vessel endothelial cell adhesion on TSP1 and TSP2. A, ␤ 1 Integrin binding sites of TSP1 and recombinant regions of TSP1 and TSP2. ␣ 4 ␤ 1 Mediates activation-dependent HUVEC (B) and AG10773A iliac vein endothelial cell (D) adhesion on N-terminal regions of TSP1 (NoC1) and TSP2 (NoC2) 30 g/mL. Unstimulated cells (2 to 2.5ϫ10 5 cells/mL, C) or cells treated with the ␤ 1 -activating antibody TS2/16 (5 g/mL, S) were incubated in the absence or presence of the ␣ 4 ␤ 1 inhibitor, phLDVP (1 mol/L). C, Morphologies of HUVECs activated using TS2/16 attaching on TSP1, NoC1, or NoC2. Barϭ50 m. E, Cell attachment (solid bars) and spreading (striped bars) on TSP1(1-175) (30 g/mL) was determined using cells activated with TS2/16 and quantified after 1 hour. Results are expressed as the number of cells/mm 2 ϮSD, from 3 experiments. *PϽ0.05 relative to control.
Materials and Methods

Cell Culture
Human umbilical vein endothelial cells (HUVECs) were maintained in M199 containing 20% FBS, 2 mmol/L glutamine, 80 g/mL endothelial cell mitogen, and 10 g/mL heparin. Human dermal microvascular endothelial cells (HDMVECs) and human lung microvascular endothelial (HMVE-L) cells were maintained as specified by the manufacturer (Clonetics). Adult iliac vein endothelial cells (AG10773A) were grown on flasks coated with 0.1% gelatin in medium M199 containing 10% FBS, 2 mmol/L glutamine, 30 g/mL endothelial cell mitogen, and 30 g/mL heparin.
Proteins, Peptides, and Antibodies
TSP1 was purified from human platelets. Recombinant trimeric proteins consisting of the N-terminal module (N), oligomeration sequence (o), and procollagen module (C) of TSP1 (NoC1) residues 1 to 356, or TSP2 (NoC2) residues 1 to 359 34 and monomeric N-terminal module of TSP1 (residues 1 to 175) 14 were prepared as described previously. Synthetic peptides containing TSP1 sequences were prepared as described. 35 Recombinant soluble 7-domain VCAM-1 (residues 1 to 674) was prepared as described. 27 VEGF was from R&D Systems, FGF2 from Prizm Pharmaceuticals, and Vitrogen type I collagen from Cohesion Technologies.
The ␤ 1 integrin-activating antibody TS2/16 was purified from hybridoma supernatant. 36 Anti-␣ 4 and anti-␣ 3 antibodies, P4C2 and Asc-1, respectively, were from Chemicon. The anti-␤ 1 blocking antibody mAb13 was provided by Dr Ken Yamada, National Institutes of Dental and Craniofacial Research, Bethesda, Md. The ␣ 4 ␤ 1 antagonist (4-((2methylphenyl)aminocarbonyl) aminophenyl)acetyl-LDVP (phLDVP) 37 was obtained from Bachem.
Endothelial Cell Functional Assays
Adhesion of endothelial cells was assessed as described. 28 Chemotaxis was assessed using modified Boyden chambers and 8-m pore membranes. Endothelial cell proliferation was quantified using a tetrazolium proliferation assay (Promega).
Integrin Expression Analyses
Cells were washed and incubated with TS2/16 or P4C2 for 1 hour. Cells were washed, incubated with FITC-conjugated anti-mouse antibody, washed, and fixed with 1% formaldehyde. Flow cytometry data were acquired using a Becton Dickinson flow cytometer. Cell lysates labeled with EZ-Link Sulfo-NHS-LC-Biotin (Pierce) were immunoprecipitated using 2 g of P4C2 or Asc-1. The immune complexes were analyzed by Western blotting.
Angiogenesis Assays
Effects of the ␣ 4 ␤ 1 -binding peptide from TSP1 and other ␣ 4 ␤ 1 antagonists on angiogenesis were evaluated using the chick chorioallantoic membrane (CAM) angiogenesis assay as described previously. 15 Muscle explant vascularization in a 3-dimensional collagen matrix was assessed essentially as described. 38 
siRNA-Mediated Knockdown of ␣ 4 ␤ 1 Integrin
Selection of the target sequence AACUAUCAACGAAA-GAACUGG from human ␣ 4 mRNA was done according to Elbashir et al. 39 siRNA duplexes were synthesized using the Silencer siRNA kit (Ambion). HUVECs were transfected using a nuclear-localized ␤-Gal expression vector alone, in combination with ␣ 4 siRNA or with ␣ 4 siRNA alone. Transfected cells were maintained in complete medium for 48 to 72 hours before use. Three siRNA sequences were screened initially, and the most active was selected. Adhesion assays were stained using 5-bromo-4-chloro-3-indoyl-␤-D-Gal to identify transfected cells.
An expanded Materials and Methods section can be found in the online data supplement available at http://circres.ahajournals.org.
Results
␣ 4 ␤ 1 Integrin Mediates Adhesion of Large-Vessel Endothelial Cells on TSP1 and TSP2
␣ 4 ␤ 1 and ␣ 6 ␤ 1 recognize N-terminal regions of both TSP1 and TSP2, 19, 27 whereas ␣ 3 ␤ 1 recognizes a sequence in this region of TSP1 that is not conserved in TSP2 35 (Figure 1A ). We recently showed that ␣ 6 ␤ 1 is not a functional TSP receptor in HUVECs. 19 However, the ␤ 1 integrin-activating antibody TS2/16 increased adhesion of HUVECs similarly on recombinant portions of both TSP1 (NoC1) and TSP2 (NoC2) ( Figure 1B ). The cells spread on NoC1 and NoC2 forming prominent lamellipodia ( Figure 1C ). These results are consistent with the similar activities of NoC1 and NoC2 for interacting with ␣ 4 ␤ 1 on T cells. 27 Recognition of N-terminal regions of TSP1 and TSP2 is at least partially dependent on ␣ 4 ␤ 1 because an ␣ 4 ␤ 1 -specific antagonist, phLDVP, partially inhibited adhesion of HUVECs and AG10773A venous endothelial cells on TSP1, NoC1, and NoC2 (PՅ0.01) ( Figures 1B and 1D ). Recombinant TSP1(1-175), which contains the ␣ 4 ␤ 1 binding site 27 but lacks the recognition site for ␣ 3 ␤ 1 , 35 also mediated HUVEC adhesion and was inhibited by phLDVP (PՅ0.007) ( Figure  1E ). Therefore, this region of TSP1 is sufficient for promoting ␣ 4 ␤ 1 -dependent endothelial cell adhesion.
To confirm a direct role of ␣ 4 ␤ 1 as an endothelial cell TSP receptor, we suppressed the expression of ␣ 4 integrin in HUVECs using RNA interference (siRNA). In cells cotransfected with a ␤-galactosidase expression plasmid and ␣ 4 siRNA, attachment on TSP1, TSP1 (1-175), and NoC2 was significantly decreased relative to control cultures transfected with the ␤-galactosidase plasmid alone (Figure 2A ). The effect of the siRNA on adhesion to TSPs was specific, in that ␣ 2 /␣ 1 ␤ 1 -mediated adhesion on type I collagen was not affected ( Figure 2A ). Loss of ␣ 4 expression in siRNAtransfected cells was confirmed by Western blotting ( Figure  2B ). Densitometric analysis showed a 5.7-fold decrease in ␣ 4 expression, whereas ␣ 3 expression did not show a significant change ( Figure 2B ). Therefore, ␣ 4 ␤ 1 is required for venous endothelial cell adhesion to TSP1 and an N-terminal region of TSP2.
␣ 4 ␤ 1 Does Not Mediate Adhesion of Microvascular Endothelial Cells
Adhesion of microvascular endothelial cells on NoC1 and NoC2 is also ␤ 1 integrin-dependent, based on complete inhibition by a ␤ 1 -blocking antibody 19 and stimulation by a ␤ 1 -activating antibody ( Figure 3A ). However, the ␣ 4 ␤ 1 inhibitor phLDVP did not significantly inhibit adhesion of either HDMVECs or HME-L cells on NoC1 or NoC2 (Figures 3A and 3B). Adhesion of microvascular cells, therefore, is mediated exclusively by ␣ 3 ␤ 1 and ␣ 6 ␤ 1 . 18, 19 Although microvascular cells exhibited no ␣ 4 ␤ 1 -dependent adhesion on TSPs, they express ␣ 4 ␤ 1 (Figures 4A and 4B ). The modest difference in ␣ 4 subunit surface expression A, HUVECs and HDMVECs were stained using antibodies specific for ␣ 4 (P4C2) and ␤ 1 (TS2/16) subunits (2 g/10 6 cells, thick lines) or isotype control (thin lines) and for surface expression analyzed by flow cytometry. B, Cell lysates from both cell types were immunoprecipitated using P4C2, resolved on SDS gels, and immunoblotted with TS2/16 (0.5 g/mL). C, Adhesion on immobilized S7D-VCAM-1 (5 g/mL) or TSP1 (40 g/mL) was measured using unstimulated (C) or TS2/16-activated HUVECs and HDMVECs (S). Attached (solid bars) and spread cells (striped bars) after 1 hour and are expressed as cells/mm 2 ϮSD, nϭ3.
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between HUVECs and HDMVECs measured by flow cytometry ( Figure 4A ) was not sufficient to account for the differences in adhesion. To exclude the possibility that ␣ 4 pairs only with ␤ 7 subunits in microvascular cells, cell lysates were immunoprecipitated using an ␣ 4 antibody and immunoblotted with a ␤ 1 antibody. The amount of ␣ 4 complexed with ␤ 1 was only slightly lower in HDMVECs than in HUVECs ( Figure 4B ). Thus, ␣ 4 ␤ 1 is present but may be maintained in an inactive state in microvascular cells. Consistent with this hypothesis, adhesion of HDMVECs to the ␣ 4 ␤ 1 ligand VCAM-1 was minimal relative to HUVECs and was not significantly stimulated by TS2/16 ( Figure 4C ).
TSP1 and TSP2 Promote Endothelial Cell Survival and Proliferation Through ␣ 4 ␤ 1 Integrin
TSP1 has context-dependent effects on endothelial cell proliferation. In solution, it inhibits proliferation, 7, 40 whereas immobilized TSP1 stimulates proliferation at least in part through ␣ 3 ␤ 1 . 18 We examined whether ␣ 4 ␤ 1 also contributes to the proliferative activity of TSP1 and whether TSP2 shares this activity. Plating HUVECs on immobilized NoC1 and NoC2 at 0.1 g/mL supported initial adhesion and cell survival, and higher concentrations dose-dependently increased cell numbers after 72 hours ( Figure 5A ). The cells did not attach or survive after 72 hour on wells without the proteins, indicating that immobilized N-terminal regions of TSP1 and TSP2 have both growth-and survival-promoting activities. Consistent with their differential ␣ 4 ␤ 1 activities, proliferation of HUVECs on NoC1 and NoC2 was greater than for HDMVECs ( Figure 5B ). Using NoC2 to avoid contributions of ␣ 3 ␤ 1 to the observed proliferative response, 18 we examined the activities of two ␣ 4 ␤ 1 antagonists ( Figure 5C ). NoC2 at Ͼ0.5 g/mL stimulated net proliferation, which was significantly inhibited by phLDVP and the ␣ 4 ␤ 1 -blocking antibody (PՅ0.04; Figure  5C ). Cell adhesion, survival, and proliferation were also promoted by the immobilized ␣ 4 ␤ 1 ligand VCAM-1 at Ͼ0.7 g/mL. Net proliferation stimulated by immobilized VCAM-1 was also inhibited by the ␣ 4 ␤ 1 antibody and phLDVP (PՅ0.02; Figure 5D ). Based on these data, ␣ 4 ␤ 1 mediates proliferative responses of venous endothelial cells to immobilized NoC2 and VCAM-1.
␣ 4 ␤ 1 Mediates Endothelial Cell Chemotaxis
TSP1-stimulated chemotaxis of murine lung capillary and bovine aortic endothelial cells was inhibited by an antibody recognizing the N-module of TSP1. 7 ␣ 3 ␤ 1 and ␣ 6 ␤ 1 contribute to this response for microvascular cells, 19 but the receptor mediating venous endothelial cell motility to TSPs has not been identified. A report that ␣ 4 ␤ 1 mediates HUVEC chemotaxis stimulated by soluble VCAM-1 41 suggested ␣ 4 ␤ 1 may be involved. TSP1, NoC1, and NoC2 stimulated chemotaxis of HUVECs with similar dose dependencies ( Figure 6A ). The ␣ 4 ␤ 1 antagonist phLDVP strongly inhibited chemotactic responses to both TSP1 and NoC2 (Figures 6B and 6C ). This inhibition was specific, because phLDVP did not inhibit the chemotactic activity of a recombinant region of fibronectin containing only its ␣ 5 ␤ 1 binding site (online Figure 1 , available in the online data supplement at http://circres. ahajournals.org). Therefore, ␣ 4 ␤ 1 plays a role in endothelial cell chemotaxis to TSP1 and TSP2.
In addition to its direct chemotactic activity, TSP1 inhibits endothelial cell motility induced by FGF2. 7, 10 In microvascular cells, this inhibition is mediated by CD36, 16 although TSP1(1-175), which lacks a CD36-binding site, also inhibits FGF2-stimulated chemotaxis of BAE cells. 14 The inhibitory activity of TSP1(1-175) was originally attributed to HSPG binding, 14 but the present data suggested that ␣ 4 ␤ 1 should also be considered. Using HUVECs, which do not express CD36, TSP1 inhibited FGF2-stimulated chemotaxis, but NoC1 and NoC2 did not ( Figure 6D) .
When VEGF was used in place of FGF2 to stimulate migration of HUVECs, NoC1 and NoC2 weakly inhibited chemotaxis but were approximately 5-fold less active than native TSP1 ( Figure 6E ). Therefore, the N-terminal region of TSP1 does not contain its inhibitory activity for FGF2mediated motility, and receptors recognizing this domain, including ␣ 4 ␤ 1 , are not involved. However, these regions of TSP1 and TSP2 do contain inhibitory activities for VEGFstimulated chemotaxis that are independent of CD36 expression. The mechanism of this inhibitory activity of TSP1 and TSP2 remains to be defined.
␣ 4 ␤ 1 Antagonists Inhibit Angiogenesis
The activities of ␣ 4 ␤ 1 to mediate endothelial adhesion, chemotaxis, and survival responses to TSP1 and TSP2 in vitro suggested that ␣ 4 ␤ 1 may mediate proangiogenic activities of both proteins. Consistent with this hypothesis, a synthetic TSP1 peptide containing its ␣ 4 ␤ 1 binding site inhibited angiogenesis in the CAM assay ( Figure 7A ). AELDVP (753) inhibited angiogenesis in CAMs overlaid with either a pure type I collagen matrix or with a collagen plus fibronectin matrix to provide an exogenous ␣ 4 ␤ 1 ligand. In both cases, the peptide was specific in that the control VALAEP (755) was inactive. Furthermore, neither peptide altered the angiogenic response in the absence of growth factors (unpublished data, 2003) .
In the presence of growth factors, native TSP1 had equivalent antiangiogenic activities in matrices of type I collagen or collagen plus fibronectin, whereas no response was observed in the absence of growth factors (Table) . In contrast to intact TSP1, NoC1 and NoC2 stimulated angiogenesis above the control both in the presence and absence of growth factors. The greater activity of NoC1 compared with NoC2 may result from engaging ␣ 3 ␤ 1 , 18 but the activity of NoC2 suggested that ␣ 4 ␤ 1 also contributes to the proangiogenic activities. Engaging ␣ 4 ␤ 1 may be sufficient to stimulate angiogenesis in the CAM, because VCAM-1 had a weak proangiogenic activity, similar to NoC2, in the absence of growth factors, and a significant stimulation in the presence of growth factors was observed on the collagen matrix (Table; PϽ0.005, nϭ9).
This stimulatory activity of VCAM-1 is specific for collagen matrices, however, because addition of soluble VCAM-1 inhibited CAM angiogenesis in a Hydron gel and in a fibronectin matrix ( Figure 7B ). Under these conditions, soluble VCAM-1 appears to be an ␣ 4 ␤ 1 antagonist. Consistent with this, the specific ␣ 4 ␤ 1 antagonist phLDVP inhibited angiogenesis in CAM assays using collagen matrices with or without fibronectin ( Figure 7B ). VCAM-1 in collagen and the N-terminal regions of TSP1 and TSP2, in contrast, may be proangiogenic because they become immobilized in the matrix.
Inhibition by three specific antagonists indicated that ␣ 4 ␤ 1 is required for angiogenesis in the CAM. Although exogenous NoC1 stimulated CAM angiogenesis, we could not determine whether TSP1 is an important endogenous ligand for ␣ 4 ␤ 1 in this response. To address this question, we used a muscle explant angiogenesis assay 38 to compare the sensitivity of neovascularization to an ␣ 4 ␤ 1 antagonist in wild-type and TSP1 Ϫ/Ϫ mice ( Figure 7C ). The ␣ 4 ␤ 1 antagonist dosedependently inhibited vascular outgrowth in explants from wild-type mice at days 3 to 9 (PՅ0.05), but not in explants from TSP1 Ϫ/Ϫ mice. Therefore, sensitivity of angiogenesis to ␣ 4 ␤ 1 antagonists in this context is clearly TSP1-dependent. Loss of inhibition in the Ϫ/Ϫ mice was not due to compensatory upregulation of TSP2, based on comparable TSP2 mRNA levels in the wild-type and null explants ( Figure 7D ).
Discussion
Leukocyte ␣ 4 ␤ 1 plays critical roles in adhesion and migration by binding to VCAM-1 on activated endothelium. 30 Although VCAM-1 can modulate angiogenesis, 41, 42 little is known about ␣ 4 ␤ 1 function in endothelial cells. We show in this study that inhibiting ␣ 4 ␤ 1 disrupts angiogenic responses in vivo and in vitro. In vitro, ␣ 4 ␤ 1 mediates proliferative, adhesive, and chemotactic responses to N-terminal regions of TSP1 and TSP2. Based on differential responses of wild-type and TSP1 null explants to an ␣ 4 ␤ 1 antagonist, the ability of endogenous TSP1 to influence muscle explant vascularization depends on this integrin. However, TSP1 is probably not the only ligand for ␣ 4 ␤ 1 that modulates vascularization. A soluble form of VCAM-1 induces chemotaxis and proliferation of HUVECs and modulates angiogenesis in both cornea 41 and CAM assays. Fibronectin, TSP2, 27 and osteopontin 43 are also ␣ 4 ␤ 1 ligands. Because angiogenesis involves smooth muscle cells and pericytes as well as endothelial cells, the functions of ␣ 4 ␤ 1 that are disrupted by ␣ 4 ␤ 1 antagonists may not be limited to endothelium.
Endothelial cells now have three identified ␤ 1 integrins that recognize TSP1, and these integrins have some overlapping functions. ␣ 3 ␤ 1 mediates adhesion and chemotaxis but has both stimulatory and inhibitory effects on proliferation. 18, 19 ␣ 6 ␤ 1 mediates adhesion and chemotaxis, but only in microvascular endothelial cells. 19 Our data show that immobilized ␣ 4 ␤ 1 ligands selectively mediate venous endothelial adhesion and stimulate cell survival and proliferation. In addition, ␣ 4 ␤ 1 mediates chemotactic responses of venous endothelial cells to soluble TSP1 and TSP2. Both ␣ 4 ␤ 1 and ␣ 3 ␤ 1 contribute to angiogenesis in the CAM. Stimulation of angiogenesis by meanϮSEM, nϭ21. C, TSP1 Ϫ/Ϫ and ϩ/ϩ mouse muscle explants were cultured in Vitrogen matrices in the absence or presence of 1 or 5 mol/L phLDVP. Vascular outgrowth responses were evaluated by measuring maximal cell migration distances in 4 quadrants from each explant. Data represent the outgrowth migration normalized to controls for 6 explants at each time point, meanϮSEM (*PϽ0.05). These results are representative of 3 independent experiments. D, RNAs from explants were amplified using GAPDH and TSP2 primersϮreverse transcriptase (RT) and analyzed after 35 cycles using a 2% agarose gel. (acetyl-VALAEP) were evaluated in a CAM assay. Polymerized matrix of type I collagen alone (circles) or in combination with fibronectin (triangles) containing either 250 ng/mesh VEGFϩ25 ng FGF2 or vehicle in the presence or absence of peptide was placed onto the CAM of day 11 chicken embryos. Angiogenesis responses ϮSEM (nϭ9 to 12) were normalized to growth factor (defined as 100%) and vehicle controls (0%). Responses were quantified 24 hours after application of matrix to the CAM surface. B, CAM angiogenesis was assessed on the indicated matrices containing either SD7-VCAM-1 or phLDVP, NoC2 demonstrates a role for ␣ 4 ␤ 1 , but the stronger proangiogenic activity of NoC1 suggests that ␣ 3 ␤ 1 and ␣ 4 ␤ 1 are both proangiogenic TSP1 receptors.
Differential regulation may be key to understanding how functions of the eight endothelial cell TSP receptors identified to date are coordinated. ␣ 4 ␤ 1 and ␣ 3 ␤ 1 1 are widely expressed in endothelium, 33, 44 but their functional regulation differs. ␣ 3 ␤ 1 is inactivated by cell-cell contact and, therefore, may function as a TSP1 receptor only during vascular remodeling. 18 ␣ 6 ␤ 1 is active only on microvascular cells, 19 whereas ␣ 4 ␤ 1 functions are largely restricted to large-vessel endothelium. ␣ 4 ␤ 1 -dependent adhesion is not regulated by cell contact (unpublished data, 2003) . CD36 is expressed and functions selectively on microvascular endothelium. 45, 46 CD36 is required for inhibition of FGF2-stimulated endothelial cell chemotaxis in vitro 16 and for inhibition of angiogenesis in the cornea. 12 Differential effects of TSP1 on HUVEC and HDMVEC proliferation at concentrations lower than 10 nmol/L 9 are also consistent with an inhibitory activity mediated by CD36.
Although native TSP1 has no proangiogenic activity in the CAM assay, NoC1, NoC2, and other contructs containing the N-domain 17, 18 are proangiogenic. Therefore, proteolytic processing that removes the inhibitory type 1 repeats could generate proangiogenic fragments of TSP1 and TSP2. Previous studies have established that native TSP1 displays proangiogenic activities under certain conditions. 47, 48 Whether these activities are mediated by intact TSP1 or by proteolytic fragments similar to NoC1 remains to be determined.
The inhibitory activities of ␣ 4 ␤ 1 antagonists in the CAM assay suggest that ␣ 4 ␤ 1 becomes activated on microvascular endothelium in vivo. Alternatively, ␣ 4 ␤ 1 may be essential for a perivascular cell contribution to angiogenesis. Although we do not know which of these cells express functional ␣ 4 ␤ 1 in vivo, the explant data show that TSP1 is essential for sensitivity of neovascularization to an ␣ 4 ␤ 1 antagonist.
Integrins play complex regulatory roles in angiogenesis. ␤ 1 Integrins are essential for angiogenesis, 49 but the roles of specific ␤ 1 integrins in this process are unclear. The ␣ 4 subunit is widely expressed in endothelial cells during vascular development, 33 but the specific role of ␣ 4 ␤ 1 in angiogenesis remains unclear. As is known for ␣ v ␤ 3 antagonists, our results using ␣ 4 ␤ 1 antagonists do not prove an essential role for ␣ 4 ␤ 1 in angiogenesis. However, like ␣ v ␤ 3 , 1 ␣ 4 ␤ 1 may be a useful pharmacological target to control pathological angiogenesis. *Angiogenic responses (percentϮSEM). Each treatment was performed 9 to 12 independent times. Angiogenic responses were normalized to a growth factor alone (100%) and vehicle (0%) matrix plugs (meshes), which were included in each experiment. In the presence of growth factors, a response Ͼ100% indicates stimulation of angiogenesis; Ͻ100% indicates inhibition of VEGF and FGF2-induced angiogenesis. In the absence of growth factors, a response Ͼ0% indicates stimulation above the vehicle control. 
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